{
    "tradingName": "Primary prophylaxis in ambulatory patients with cancer receiving systemic therapy.",
    "account": [
      {
        "name": "Accou",
        "product": { "name": "patients with cancer at low risk for thrombosis receiving systemic therapy, no thromboprophylaxis is recommend" }
      },
      {
        "name": "Au",
        "product": { "name": "Patients with cancer at intermediate risk of thrombosis thromboprophylaxis with a DOAC (apixaban or rivaroxaban)  or no thromboprophylaxis " }
      },
      {
        "name": "Aumm",
        "product": { "name": "patients with cancer at high risk for thrombosis receiving systemic therapy, thromboprophylaxis with a DOAC (apixaban or rivaroxaban) over no thromboprophylaxis is recommended " }
      }
    ]
   
  }
  